1-4 of 4
Jean Viallet, MD
Close
Sort by
Journal Articles

The Combination of a Histone Deacetylase (HDAC) Inhibitor with the BCL-2 Inhibitor GX15-070 Has Synergistic Antileukemia Effect by Inducing Both Apoptotic and Autophagic Pathways.

Yue Wei, PhD, Tapan Kadia, MD, Weigang Tong, MD, PhD, Susan O’Brien, MD, Jean Viallet, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2008) 112 (11): 1633.
https://doi.org/10.1182/blood.V112.11.1633.1633
Published: 2008
Journal Articles

A Phase II Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by a 24-h Continuous Infusion Every 2 Weeks to Patients with Chronic Idiopathic Myelofibrosis (CIMF).

Srdan Verstovsek, MD, Azra Raza, MD, Aaron D. Schimmer, MD, Jean Viallet, MD, Hagop Kantarjian, MD
Journal: Blood
Blood (2007) 110 (11): 3553.
https://doi.org/10.1182/blood.V110.11.3553.3553
Published: 2007
Journal Articles

A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by Continuous Infusion for up to Four Days to Patients with Hematological Malignancies.

Aaron D. Schimmer, MD, Joseph Brandwein, MD, Susan M. O’Brien, MD, Hagop Kantarjian, MD, Bruce D. Cheson, MD, Mark D. Minden, MD, Karen Yee, MD, Andre Schuh, MD, Vikas Gupta, MD, Jean Viallet, MD, Gautam Borthakur, MD
Journal: Blood
Blood (2007) 110 (11): 892.
https://doi.org/10.1182/blood.V110.11.892.892
Published: 2007
Journal Articles

A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor GX15-070 Administered Intravenously (IV) Every 3 Weeks to Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL).

Susan O’Brien, MD, Thomas J. Kipps, MD, Stefan Faderl, MD, Michael Crump, MD, Michael J. Keating, MD, Blanche Anderson, Claudia Soho, Jan Bole, Ruth Turner, Jean Viallet, MD, Bruce D. Cheson, MD
Journal: Blood
Blood (2005) 106 (11): 446.
https://doi.org/10.1182/blood.V106.11.446.446
Published: 2005